CervoMed Statistics
Total Valuation
CervoMed has a market cap or net worth of $20.12 million. The enterprise value is $523,144.
Important Dates
The last earnings date was Friday, November 6, 2026, before market open.
| Earnings Date | Nov 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CervoMed has 15.13 million shares outstanding. The number of shares has increased by 23.36% in one year.
| Current Share Class | 15.13M |
| Shares Outstanding | 15.13M |
| Shares Change (YoY) | +23.36% |
| Shares Change (QoQ) | +47.58% |
| Owned by Insiders (%) | 25.92% |
| Owned by Institutions (%) | 9.03% |
| Float | 9.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2,513.91 |
| Forward PS | n/a |
| PB Ratio | 1.26 |
| P/TBV Ratio | 1.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 268.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.37, with zero debt.
| Current Ratio | 5.37 |
| Quick Ratio | 4.93 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -131.52% and return on invested capital (ROIC) is -84.24%.
| Return on Equity (ROE) | -131.52% |
| Return on Assets (ROA) | -70.33% |
| Return on Invested Capital (ROIC) | -84.24% |
| Return on Capital Employed (ROCE) | -168.39% |
| Weighted Average Cost of Capital (WACC) | -17.68% |
| Revenue Per Employee | $582 |
| Profits Per Employee | -$1.90M |
| Employee Count | 15 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.98% in the last 52 weeks. The beta is -3.99, so CervoMed's price volatility has been lower than the market average.
| Beta (5Y) | -3.99 |
| 52-Week Price Change | -83.98% |
| 50-Day Moving Average | 2.26 |
| 200-Day Moving Average | 3.21 |
| Relative Strength Index (RSI) | 31.34 |
| Average Volume (20 Days) | 1,004,474 |
Short Selling Information
The latest short interest is 1.21 million, so 8.02% of the outstanding shares have been sold short.
| Short Interest | 1.21M |
| Short Previous Month | 1.21M |
| Short % of Shares Out | 8.02% |
| Short % of Float | 12.61% |
| Short Ratio (days to cover) | 3.54 |
Income Statement
In the last 12 months, CervoMed had revenue of $8,726 and -$28.52 million in losses. Loss per share was -$2.60.
| Revenue | 8,726 |
| Gross Profit | -21.80M |
| Operating Income | -29.23M |
| Pretax Income | -28.52M |
| Net Income | -28.52M |
| EBITDA | n/a |
| EBIT | -29.23M |
| Loss Per Share | -$2.60 |
Full Income Statement Balance Sheet
The company has $19.60 million in cash and no debt, with a net cash position of $19.60 million or $1.30 per share.
| Cash & Cash Equivalents | 19.60M |
| Total Debt | n/a |
| Net Cash | 19.60M |
| Net Cash Per Share | $1.30 |
| Equity (Book Value) | 17.36M |
| Book Value Per Share | 1.15 |
| Working Capital | 17.36M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -26.59M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -26.59M |
| FCF Per Share | -$1.76 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | -334,924.87% |
| Pretax Margin | -326,822.54% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CervoMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -23.36% |
| Shareholder Yield | -23.36% |
| Earnings Yield | -195.19% |
| FCF Yield | -121.20% |
Analyst Forecast
The average price target for CervoMed is $15.20, which is 1,042.86% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.20 |
| Price Target Difference | 1,042.86% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CervoMed has an Altman Z-Score of -3.84 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.84 |
| Piotroski F-Score | 1 |